HK1186192A1 - 抗癌融合蛋白 - Google Patents

抗癌融合蛋白

Info

Publication number
HK1186192A1
HK1186192A1 HK13113599.3A HK13113599A HK1186192A1 HK 1186192 A1 HK1186192 A1 HK 1186192A1 HK 13113599 A HK13113599 A HK 13113599A HK 1186192 A1 HK1186192 A1 HK 1186192A1
Authority
HK
Hong Kong
Prior art keywords
fusion protein
anticancer fusion
anticancer
protein
fusion
Prior art date
Application number
HK13113599.3A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Krzysztof Kazimierz Lemke
Sebastian Pawlak
Bartlomiej Zerek
Original Assignee
Adamed Sp Zo O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Adamed Sp Zo O filed Critical Adamed Sp Zo O
Publication of HK1186192A1 publication Critical patent/HK1186192A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK13113599.3A 2010-12-03 2013-12-06 抗癌融合蛋白 HK1186192A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PL39459711 2011-04-18
PCT/EP2011/071719 WO2012072815A1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
HK1186192A1 true HK1186192A1 (zh) 2014-03-07

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13113599.3A HK1186192A1 (zh) 2010-12-03 2013-12-06 抗癌融合蛋白

Country Status (27)

Country Link
US (1) US9161991B2 (zh)
EP (1) EP2646464B1 (zh)
JP (1) JP5759557B2 (zh)
KR (1) KR101952460B1 (zh)
CN (1) CN103237808B (zh)
AU (1) AU2011334868B2 (zh)
BR (1) BR112013013548B8 (zh)
CA (1) CA2814595C (zh)
CY (1) CY1116646T1 (zh)
DK (1) DK2646464T3 (zh)
EA (1) EA024452B1 (zh)
ES (1) ES2545895T3 (zh)
HK (1) HK1186192A1 (zh)
HR (1) HRP20150664T1 (zh)
HU (1) HUE027068T2 (zh)
IL (1) IL226207A (zh)
ME (1) ME02224B (zh)
MX (1) MX337436B (zh)
NZ (1) NZ609216A (zh)
PL (1) PL2646464T3 (zh)
PT (1) PT2646464E (zh)
RS (1) RS54057B1 (zh)
SG (2) SG189370A1 (zh)
SI (1) SI2646464T1 (zh)
SM (1) SMT201500203B (zh)
WO (1) WO2012072815A1 (zh)
ZA (1) ZA201303449B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2670426B1 (en) * 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
EP4133085A1 (en) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4308594A2 (en) 2021-03-16 2024-01-24 CytomX Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko) 2022-11-10 2024-05-17 제주대학교 산학협력단 리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240072614A (ko) 2022-11-17 2024-05-24 제주대학교 산학협력단 감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0835305B1 (en) 1995-06-29 2005-11-23 Immunex Corporation Cytokine that induces apoptosis
EP1351709B8 (en) * 2000-06-09 2004-12-22 The Government of The United States of America, as represented by The Department of Health and Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
AU2001288025A1 (en) 2000-09-05 2002-03-22 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
US7666989B2 (en) 2003-11-03 2010-02-23 Beijing Sunbio Biotech Co., Ltd. Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
EP1915626B1 (en) 2005-08-16 2011-11-09 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
EP2484691B1 (en) * 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
CA2814595A1 (en) 2012-06-07
BR112013013548B8 (pt) 2022-11-08
EP2646464A1 (en) 2013-10-09
ES2545895T3 (es) 2015-09-16
WO2012072815A1 (en) 2012-06-07
EA201390820A1 (ru) 2013-12-30
SG10201509676UA (en) 2015-12-30
EA024452B1 (ru) 2016-09-30
MX2013006213A (es) 2013-07-29
SG189370A1 (en) 2013-05-31
NZ609216A (en) 2014-05-30
RS54057B1 (en) 2015-10-30
ME02224B (me) 2016-02-20
HUE027068T2 (en) 2016-08-29
KR101952460B1 (ko) 2019-02-27
MX337436B (es) 2016-03-03
CA2814595C (en) 2020-06-16
AU2011334868A1 (en) 2013-05-02
DK2646464T3 (en) 2015-08-24
PL2646464T3 (pl) 2015-10-30
PT2646464E (pt) 2015-10-05
KR20130122764A (ko) 2013-11-08
US20130251676A1 (en) 2013-09-26
BR112013013548A2 (pt) 2016-10-11
ZA201303449B (en) 2014-01-29
US9161991B2 (en) 2015-10-20
BR112013013548B1 (pt) 2022-03-29
AU2011334868B2 (en) 2015-01-22
HRP20150664T1 (hr) 2015-07-31
JP2014502158A (ja) 2014-01-30
SI2646464T1 (sl) 2015-07-31
IL226207A0 (en) 2013-07-31
JP5759557B2 (ja) 2015-08-05
IL226207A (en) 2016-07-31
CY1116646T1 (el) 2017-03-15
CN103237808A (zh) 2013-08-07
CN103237808B (zh) 2016-02-24
SMT201500203B (it) 2015-10-30
EP2646464B1 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
HRP20150241T1 (en) Anticancer fusion protein
HK1201727A1 (zh) 抗癌融合蛋白
HK1186192A1 (zh) 抗癌融合蛋白
HK1201848A1 (zh) 抗癌融合蛋白
IL226205A0 (en) anticancer fusion protein
SG10202100341XA (en) Npp1 fusion proteins
IL226481A0 (en) Enzymes@Maochim
EP2698386A4 (en) FUSION PROTEIN
EP2683742A4 (en) NPP1 FUSION PROTEIN
ZA201308597B (en) Anticancer fusion protein
EP2657337A4 (en) FUSION PROTEIN
GB201016494D0 (en) Polypeptide
EP2521787A4 (en) IMPROVED PROTEIN EXPRESSION
ZA201207425B (en) Fusion protein
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201007955D0 (en) Somatosatin fusion proteins
GB201010202D0 (en) Fusion polypeptides
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins